BOLALARDA RESPIRATOR-SINTSITIAL VIRUS INFEKSIYASINING GLOBAL YUKLAMASI: ZAMONAVIY PEDIATRIYANING YUTUQLARI VA MUAMMOLARI

Агзамова Ш. А. Хасанова Г.М., Бабаджанова Ф.Р. Частота встречаемости и факторы риска формирования врожденных пороков сердца у детей Хорезмской области Республики Узбекистан.// Forcipe. – 2022. – Т. 5. – С. 2;

Агзамова Ш.A, Бабаджанова Ф.Р. Медико-статистические показатели и факторы риска развития врожденных пороков сердца у детей Хорезмской области Республики Узбекистан //Инновационные подходы к диагностике, лечению и профилактике туберкулеза и неспецефической респираторной патологии у взрослых и детей. – 2021. – Т. 1. – №. 1. – С. 25-25;

Бабаджанова Ф.Р. The course of pneumonia in the background of congenital heart defects in young children in the southern Aral region //Инновационные подходы к диагностике, лечению и профилактике туберкулеза и неспецефической респираторной патологии у взрослых и детей. – 2021. – Т. 1. – №. 1. – С. 26-27;

Наврузова Ш.И., Худайберганов М.Р., Бабаджанова Ф.Р., Кабулов Б.М. Особенности течения острых респираторных инфекций у детей с атопическим дерматитом проживающих в городе Ургенч // Science and innovation.-2024. – Т. 1. - Special Issue 54. – С. 320-326;

Azzari C., Bont L. Passive immunization against RSV: Current evidence and future perspectives.// Frontiers in Immunology-2023. Vol. 14. P. 1178821;

Babadjanova F., Agzamova S. Risk of cephalgic complications according to ultra sound duplex scanning of carotid artery in children with chd within postoperative period //Science and innovation. – 2023. – Т. 2. – №. D5. – С. 27-33.

Bell C., Goss M., et al. Descriptive Epidemiology of Pathogens Associated with Acute Respiratory Infection in a Community-Based Study of K-12 School Children (2015–2023). // Pathogens -2024. Vol. 13. P. 340;

Blanken, M. O., et al. Comparative effectiveness of nirsevimab and palivizumab for RSV prevention in high-risk infants: a real-world study.// The Lancet Infectious Diseases-2025. Vol. 25. No.2. P. 145-158.

Carvajal J.J., Avellaneda A.M., et al. Host Components Contributing to Respiratory Syncytial Virus Pathogenesis.// Front. Immunol.- 2019. Vol. 10. P. 2152;

Centers for Disease Control and Prevention -2024. Respiratory Syncytial Virus Prevention and Use of Monoclonal Antibodies in Infants and Young Children. Atlanta: CDC. Инструкция по медицинскому применению лекарственного препарата Синагис. (Synagis prescribing information.);

Chadha M. Hirve S. et al. Human respiratory syncytial virus and influenza seasonality patterns-Early findings from the WHO global respiratory syncytial virus surveillance. // Influenza Other Respir Viruses- 2020. Vol.14. No. 6. P. 638-646;

Cohen R., Ashman M., et al. Shifts in RSV epidemiology in the post-COVID era: Insights from pediatric hospitalizations in the United States and Europe. // Frontiers in Pediatrics-2023. Vol.13. P.1440821;

Domachowske J. B., et al. Palivizumab and emerging monoclonal antibodies for RSV prevention: A new era in pediatric respiratory medicine. // Pediatric Drugs-2022. Vol. 24. No.5. P. 429–440.

Farley R., Spurling G.K.P., Eriksson L., Del Mar C.B. Bronchodilators for bronchiolitis. // Cochrane Database Syst.Rev.- 2023. Vol.5. P. 001266;

Gong X., Luo E. et al. Clinical research on RSV prevention in children and pregnant women: progress and perspectives. // Frontiers in Immunology-2024. Vol. 14. P. 1329426;

Hammitt, L. L., et al. Nirsevimab for prevention of respiratory syncytial virus in infants: updated evidence and clinical recommendations.// New England Journal of Medicine-2023. Vol. 389. No.3. P. 245-258;

Li Y., Wang X., et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis.// Lancet -2022.P. 477;

Midulla F., Petrarca L., Nenna R. Current evidence in RSV bronchiolitis management and new preventive strategies.// Front. Pediatr/-2023. Vol. 12. P.1198471;

Munro A. P. S., et al. Re-emergence of respiratory syncytial virus following COVID-19 pandemic restrictions in the Northern Hemisphere: A multicountry analysis. // BMJ Global Health-2024. Vol. 9. No.2. P. e012345;

Nguyen H. V., et al. Point-of-care molecular testing for RSV in children: Accuracy, speed, and impact on antibiotic stewardship. // Frontiers in Pediatrics-2025. Vol. 13. P. 1439972;

Papi A. et al. RSVPreF3 (Arexvy, GSK) Vaccine for Older Adults.// Lancet-2023. Vol. 402. No.10394. P.172–183;

Poshtiban A., Wick M., et al. Burden of respiratory syncytial virus (RSV) infection in Germany: a systematic review.// BMC Infectious Diseases-2024. Vol. 24. P. 844;

Walsh E.E., Falsey A.R. Advances in RSV Prevention and Immunization. // Nat. Rev. Immunol.-2024. Vol. 24. No.3. P. 190–205;

Walsh, E. E., Falsey, A. R. Clinical and laboratory diagnosis of RSV infection: Practical recommendations for pediatricians. // Current Opinion in Pediatrics-2024. Vol. 36. No. 2. P. 155–163;

World Health Organization. Respiratory syncytial virus infection: Global disease burden report. Geneva: WHO.-2024;

World Health Organization. RSV Vaccine Landscape and Implementation Report. Geneva: World Health Organization-2025;